- $2.44bn
- $3.21bn
- $6.32bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 15.26 | ||
| PEG Ratio (f) | 1.64 | ||
| EPS Growth (f) | 10.27% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.81 | ||
| Price to Tang. Book | 6.36 | ||
| Price to Free Cashflow | 8.01 | ||
| Price to Sales | 0.38 | ||
| EV to EBITDA | 7.73 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 5.82% | ||
| Return on Equity | 6.01% | ||
| Operating Margin | 3.91% | ||
Financial Summary
| Year End 31st Dec | Unit | 2021 | 2022 | 2023 | 2024 | 2025 | 2026E | 2027E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 4,870.4 | 5,129.69 | 5,409.48 | 5,966.07 | 6,324.34 | 6,461.92 | 6,723.88 | 6.75% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | -7.22 | +16.27 | +384.62 | -21.57 | -21.55 | +17.31 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Ardent Health, Inc., formerly Ardent Health Partners, Inc., is a provider of healthcare in mid-sized urban communities across the United States. Through its subsidiaries, the Company delivers care through a system of 30 acute care hospitals and approximately 280 sites of care with over 1,800 affiliated providers across six states. It provides both general and specialty services, including internal medicine, general surgery, cardiology, oncology, orthopedics, women’s services, neurology, urology, and emergency services, within inpatient and ambulatory care settings. In addition to its 30 acute care hospitals, it operates a network of ambulatory facilities and telehealth services, including primary care and specialty care clinics, ambulatory surgery centers (ASCs), urgent care centers, free-standing emergency departments, and diagnostic imaging centers. It operates a consumer-centric healthcare platform focused on creating relationships with its patients across multiple care settings.
Directors
- Alfred Lumsdaine CFO (60)
- Mark Sotir NEC (62)
- Stephen Petrovich EVP (59)
- Peter Bulgarelli DRC (66)
- Peter Bynoe IND (74)
- Suzanne Campion IND (64)
- David Caspers PRE (55)
- Robert Demichiei IND (61)
- Last Annual
- December 31st, 2025
- Last Interim
- June 30th, 2026
- Incorporated
- June 29th, 2015
- Public Since
- July 18th, 2024
- No. of Shareholders
- 158
- No. of Employees
- 19,500
- Sector
- Healthcare Providers & Services
- Industry
- Healthcare
- Exchange
New York Stock Exchange- Shares in Issue
- 141,045,907
- Address
- 340 SEVEN SPRINGS WAY, SUITE 100, BRENTWOOD, 37215
- Web
- https://ardenthealth.com
- Phone
- +1 6152963000
- Contact
- Dave Styblo
- Auditors
- Ernst & Young LLP
Latest News for ARDT
Upcoming Events for ARDT
Q4 2026 Ardent Health Inc Earnings Release
Similar to ARDT
agilon health
New York Stock Exchange
American Well
New York Stock Exchange
AMN Healthcare Services
New York Stock Exchange
Auna SA
New York Stock Exchange
Brookdale Senior Living
New York Stock Exchange
FAQ
As of Today at 18:20 UTC, shares in Ardent Health are trading at $17.30. This share price information is delayed by 15 minutes.
Shares in Ardent Health last closed at $17.30 and the price had moved by +19.64% over the past 365 days. In terms of relative price strength the Ardent Health share price has outperformed the S&P500 Index by +9.13% over the past year.
The overall consensus recommendation for Ardent Health is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreArdent Health does not currently pay a dividend.
Ardent Health does not currently pay a dividend.
Ardent Health does not currently pay a dividend.
To buy shares in Ardent Health you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $17.30, shares in Ardent Health had a market capitalisation of $2.44bn.
Here are the trading details for Ardent Health:
- Country of listing: United States
- Exchange: NYQ
- Ticker Symbol: ARDT
Based on an overall assessment of its quality, value and momentum Ardent Health is currently classified as a Super Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Ardent Health is $14.64. That is 15.38% below the last closing price of $17.30.
Analysts covering Ardent Health currently have a consensus Earnings Per Share (EPS) forecast of $0.99 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ardent Health. Over the past six months, its share price has outperformed the S&P500 Index by +71.95%.
As of the last closing price of $17.30, shares in Ardent Health were trading +71.01% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ardent Health PE ratio based on its reported earnings over the past 12 months is 15.26. The shares last closed at $17.30.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ardent Health's management team is headed by:
- Alfred Lumsdaine - CFO
- Mark Sotir - NEC
- Stephen Petrovich - EVP
- Peter Bulgarelli - DRC
- Peter Bynoe - IND
- Suzanne Campion - IND
- David Caspers - PRE
- Robert Demichiei - IND